Articles tagged with Chimeric Antigen Receptors
Researchers at Massachusetts General Hospital have created a new method for immune therapy that targets two antigens on the surface of brain tumors, eliminating 80% of tumors in models. The technique holds promise for treating other solid tumors and overcomes issues with blood-brain barrier penetration.
Researchers found that eliminating key gene regulatory factors, such as NR4A and TOX, fortifies T cell attack on melanoma cells, leading to improved tumor rejection and survival. This discovery suggests a potential strategy for extending CAR T-based immunotherapy to solid tumors.
A study by Brigham and Women's Hospital found that 77% of patients experienced at least one neurological symptom after CAR-T treatment, which were often temporary. The symptoms included encephalopathy, headache, tremor, weakness, and language dysfunction, with most effects being reversible.
The CRB-401 phase 1 study of bb2121, a BCMA-targeted CAR T-cell therapy, demonstrated manageable safety and deep and durable responses in heavily pre-treated patients. Treatment resulted in an 85% objective response rate with 73% achieving ≥ VGPR.
A new CAR molecule has been developed that kills cancer cells with less toxicity, allowing for remissions without serious side effects. Researchers have produced no severe side effects in patients with lymphoma, showing promise for a safer version of the therapy
A research team developed an artificial chemical receptor that effectively facilitates viral binding to T cells, increasing transduction efficiency by up to 80%. The technique is safe and efficient for human primary T cells and shows great potential for clinical engineered T lymphocyte manufacturing.
Researchers at Boston Children's Hospital and MIT have developed nanobodies that can target the tumor micro-environment, allowing for more effective treatment of solid tumors. The nanobodies were tested in mouse models of melanoma and colon cancer, showing promising results in slowing tumor growth and improving survival rates.
Scientists visualized CAR T cells fighting blood cancer for the first time, revealing key interactions and behaviors. The study showed that CAR T cells can directly kill tumor cells within minutes, but their effectiveness is hindered by aggregation and infiltration issues.
Dr. Carl June receives the 2019 Harrington Prize for his contributions to CAR T therapy, a revolutionary cancer treatment. The prize honors his development of new strategies and culture systems that have enabled CAR T clinical trials.
CAR T cells kill cancer cells directly, rather than relying on other immune cells. Reducing encounters with circulating B cells can enhance CAR T cell infiltration and persistence, improving treatment outcomes.
A mesothelin-targeted CAR T-cell therapy demonstrated antitumor activity and acceptable toxicity in a phase I clinical trial for patients with malignant pleural disease. The therapy showed significant tumor regression and reduced mesothelin-related peptide levels in the blood.
A phase I clinical trial found that a combination of chemotherapy and HER2-targeted CAR T cells is safe and effective in treating advanced sarcoma, with some patients experiencing complete responses. The therapy showed promising antitumor activity and minimal treatment-related toxicities.
A preclinical study found that combining CAR T-cell therapy with photothermal ablation suppressed melanoma tumor growth for up to 20 days in mice. Among the treated mice, 33% remained tumor-free after 20 days.
A new study by Marko Radic and colleagues shows that CAR T cells can significantly reduce disease symptoms and progression in mice with lupus, improving lifespan and reducing inflammation. The findings offer a renewed optimism for eliminating B cells as a therapeutic option for lupus.
Researchers at the La Jolla Institute of Immunology have identified Nr4a transcription factors as a key regulator of T cell exhaustion in solid tumors. By deleting these proteins from CAR T cells, mice with tumors showed improved survival and tumor regression, offering new hope for effective cancer immunotherapies.
Researchers discovered that second-generation CARs stimulate CD3 signaling more effectively than third-generation receptors and activate downstream signaling messengers. This may contribute to superior antitumor efficacy. The study aims to improve CAR designs and lead to better understanding of immunotherapy.
The ESMO Immuno-Oncology Congress highlighted promising new technologies for cancer treatment, including multiplex immunohistochemistry and bispecific antibodies. Chimeric antigen receptor T-cell therapy and neoantigen therapeutics also showed promise in treating a greater proportion of patients with cancer.
Children's Hospital of Philadelphia researchers present updated efficacy and safety data on Kymriah, a personalized CAR T-cell gene immunotherapy for aggressive blood cancers. The therapy achieved an 82% remission rate within three months in patients with relapsed or refractory ALL.
A follow-up analysis of axi-cel-treated patients with diffuse large B-cell lymphoma (DLBCL) reported that 51% were still alive two years post-treatment. The study found that 83% achieved a reduction in cancer activity, and 39% had ongoing responses. CAR-T cell persistence and B-cell recovery were also observed in most patients.
The study found nearly 40% of large B cell lymphoma patients remained in remission beyond 2 years after receiving Yescarta treatment. Patients with refractory disease showed durable responses, giving hope for a cure.
A global clinical trial has shown that chimeric antigen receptor (CAR) T cell therapy can lead to long-lasting remissions in patients with relapsed/refractory diffuse large B-cell lymphoma. The treatment, known as Kymriah, modified patients' own immune T cells to target cancer cells and achieved high remission rates.
Researchers at Fred Hutchinson Cancer Center present promising results on CAR T-cell therapy for chronic lymphocytic leukemia and multiple myeloma. The studies show potential for improved outcomes and increased survival rates for patients with difficult-to-treat blood cancers.
Research from the Abramson Cancer Center presents findings on CAR T combinations, timing of therapy, and patient access. Studies evaluate effectiveness in multiple myeloma patients, Chronic Lymphocytic Leukemia (CLL) patients, and lymphoma patients with high-risk profiles.
Researchers have discovered how engineered protein receptor CAR activates cancer-fighting cells, shedding light on effective treatments and side effects. By understanding phosphorylation processes, they aim to design better cancer-fighting CARs with fewer side effects.
Scientists have developed a first-of-its-kind model of immune responses in cellular immunotherapies, such as stem cell transplantation and CAR T-cell therapies. This breakthrough research aims to personalize treatments and reduce complications like graft-versus-host disease. The model has the potential to identify optimal donors for tr...
Scientists uncover how T cells respond to outside signals, activating them to attack diseased cells. The findings may help fine-tune T-cell therapies for individual patients.
Xiuli Wang's research aims to create a single infusion therapy that can treat HIV, eliminating the need for lifelong antiretroviral drug treatment. The innovative approach combines chimeric antigen receptor (CAR) T cells with a cytomegalovirus vaccine to stimulate the immune system.
Researchers at Penn discovered a new, rare mechanism that allows leukemia cells to relapse after CAR T cell therapy by masking the target protein CD19. This finding emphasizes the need for precise manufacturing processes to ensure the effectiveness of this treatment.
Researchers at Fred Hutchinson Cancer Center compared two common CAR designs in lab models and found that the CD28 CAR showed faster and stronger activity, while the 4-1BB CAR was more effective in clearing cancer cells. The study provides insights into how to improve immunotherapy by designing future generations of CAR T-cell therapies.
The guidelines outline lessons learned by experts in various fields to identify early signs and symptoms of treatment-related toxicity, detailing ways to manage it. Key recommendations include monitoring for cytokine release syndrome and addressing parent and/or caregiver concerns.
The SLAS Technology special issue showcases advancements in cell separation methods, bioreactor systems and automation to improve the manufacturing process of cell-based therapies. These technologies aim to decrease costs and enhance safety while expanding applications beyond oncology.
A pioneering CAR T-cell immunotherapy trial has been launched at Seattle Children's for children and young adults with relapsed or refractory HER2-positive central nervous system (CNS) tumors. The trial aims to provide these patients with a second line of defense by delivering cancer-fighting CAR T cells directly into the brain.
Scientists have developed a powerful method to create synthetic orthogonal receptor-ligand pairs that bind with high selectivity, triggering intended functions without interfering with natural activities. This design approach can be used to reprogram cellular functions in cell-engineering applications.
A new study published in Psychoneuroendocrinology found that veterans with PTSD who use service dogs exhibit higher cortisol awakening response and area under the curve compared to those on the waitlist. This suggests potential physiological benefits from having a service dog, including reduced stress levels and improved sleep quality.
Researchers developed a new approach to treat Acute Myeloid Leukemia (AML) with CAR T cells by removing CD33 from healthy blood-forming stem cells using CRISPR/Cas9. This makes the cancer-specific antigen unique to leukemia cells, allowing CAR T cells to attack without harming normal bone marrow.
A 2013 CLL patient achieved complete remission with a single CAR T cell infusion, sparking insights into the human genome and immune response that may enhance response rates. The successful treatment was linked to the specific location of the CAR gene within the patient's T cell DNA.
Dr. Michel Sadelain shares his role in advancing CAR T-cell therapy, a rapidly evolving field that targets cancer cells. He describes the FDA approval of the first CAR T-cell therapy and predicts next-generation technology advancements.
A new phase 1 trial has shown that CAR T therapy CYAD-01 can induce a complete remission in a patient with acute myeloid leukemia, lasting nine months. This breakthrough is significant as it is the first time CAR T therapy has been effective without preconditioning chemotherapy.
Researchers identified a subset of healthier T cells, marked by CD8 and CD27 expression, that correlate with clinical responses in CLL patients. The findings suggest a new patient-selection tool for CAR T cell therapy and potential improvements through emerging cell manufacturing techniques.
Japanese researchers at Osaka University have identified a key cellular protein, Ebf3, involved in maintaining the bone marrow niche. The study found that Ebf3-deficient CAR cells take on bone-synthesizing properties, which has significant clinical implications for regenerative therapies.
Researchers found that antibiotics can hinder the efficacy of some cancer treatments, particularly adoptive T-cell therapy, by impacting the gut microbiota. However, CAR T-cell therapy appears to be less affected by antibiotic use.
A global clinical trial of CAR T-cell therapy tisagenlecleucel found that 61% of children and young adults achieved complete remission after treatment, with durable responses lasting months or years. Most side effects were short-lived and reversible, with overall survival rates exceeding 90% at six months.
Researchers developed a gene therapy approach using CAR T-cells to target and destroy HIV-infected cells, achieving sustained immunity of over two years in test animals. The engineered cells effectively attacked and killed HIV-infected cells without adverse effects.
CAR T-cell therapies have demonstrated durable remission and survival rates of over 59% for patients with refractory NHL. Researchers found that sustained responses were consistent across long-term follow-up analyses, suggesting potential for these therapies as the standard of care for hematologic malignancies.
A Phase 2 study of axi-cel, a CD19-targeting CAR T cell therapy, reported remarkable improvement in outcomes for patients with relapsed or refractory large B-cell lymphoma. The study showed that 42% of patients remained in remission at 15 months, with complete responses in 54% and measurable responses in 82%.
The Kymriah treatment demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients, with significant durability in responses seen across multiple trials. Durable remission rates were observed among 43% of DLBCL patients in the single-site pilot study and 73% at six months in the global trial.
Researchers from the University of Pennsylvania's Abramson Cancer Center have shown encouraging results in treating multiple myeloma patients with CAR T cell therapy and an experimental monoclonal antibody. The studies targeted the B-Cell Maturation Antigen (BCMA) receptor, which is highly expressed in myeloma cells.
Researchers at Osaka University developed a new strategy for multiple myeloma immunotherapy by identifying a novel therapeutic target, MMG49, specifically recognizing integrin β7. The resulting CAR-T treatment showed anti-MM effects without damaging normal blood cells.
A clinical trial suggests a new form of gene therapy, targeting CD22, achieved significant remission rates in children and young adults with treatment-resistant B-cell leukemia. The therapy was well-tolerated and showed promise in patients who had previously failed anti-CD19 CAR T-cell treatment.
Researchers launch PLAT-05 trial to develop a more robust defense against cancer cells, aiming to cut the rate of relapse by almost half. The new therapy will target both CD19 and CD22 proteins on cancer cells, providing long-term remission for patients.
A new study by Oregon State University shows that Brazil's environmental land registration program has slowed down deforestation on private land, particularly in the Amazon region. The CAR (Cadastro Ambiental Rural) system allows landowners to demonstrate compliance with regulations and provides a mechanism for government monitoring.
CAR T-cell therapy, approved by the FDA, has been shown to double long-term survival rates for patients with relapsed or refractory diffuse large B-cell lymphoma. The treatment, offered at UChicago Medicine, involves reprogramming a patient's immune system to detect and destroy cancer cells.
A study has identified potential biomarkers to predict patients at increased risk of severe neurotoxicity after receiving CD19 CAR T-cell therapy. Patients with early onset of CRS were found to be more susceptible to severe neurotoxicity.
Scientists have developed a new strategy to reengineer patient immune system cells to fight HIV. The approach shows benefit in human cell cultures and mice, with T cells expressing the enhanced CAR protein being over 50 times more effective than those with the original CAR.
The approved gene therapy Kymriah offers hope for children and young adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. However, its high cost and limited accessibility pose significant challenges for policy-makers and patients alike.
Researchers developed guidelines to handle CAR T cell side effects, including cytokine release syndrome and neurological toxicity. The new algorithms provide conservative and tailored treatment options to recognize and stage emerging side effects.
Researchers report a remarkable treatment response in a patient with recurrent diffuse large-B-cell lymphoma (DLBCL), where CAR T-cell therapy induced complete remission of a brain metastasis. The treatment also showed spontaneous re-expansion of CAR T-cells after a subcutaneous tumor recurrence, leading to further research into the me...
Research finds that intensive yoga and meditation retreats positively impact brain-derived neurotrophic factor (BDNF), cortisol awakening response, and inflammatory markers. Participants experienced improved subjective wellbeing, mindfulness, and reduced anxiety and depression.
A new SU2C-Lustgarten Foundation team aims to apply CAR T-cell therapy to pancreatic cancer, a deadly form of cancer with low five-year survival rate. The team will focus on epigenetics and exploring new therapies targeting mesothelin in pancreatic cancer.
Researchers found genetically modified CAR T cells successfully migrated to and penetrated glioblastoma tumors, but triggered an immunosuppressive tumor microenvironment. To overcome resistance, existing immunotherapies targeting checkpoint inhibitors may be necessary.